학술논문
Allogeneic stem cell transplantation as a curative option in relapse/refractory diffuse large B cell lymphoma: Spanish multicenter GETH/GELTAMO study
Document Type
Article
Author
Bento, Leyre; Gutiérrez, Antonio; Novelli, Silvana; Montoro, Juan; Piñana, J. L.; López-Corral, Lucía; Cabrero, Mónica; Martín-Sancho, Alejandro; Gutiérrez-García, Gonzalo; Ortiz-Moscovich, Marcela; Bastos-Oreiro, Mariana; Dorado, Nieves; Pérez, Ariadna; Hernani, Rafael; Ferrà, Christelle; Parody, Rocío; García-Cadenas, Irene; Herrera, Pilar; Rodríguez, Guillermo; Rodríguez, Nancy; Martín, Carmen; Yáñez, Lucrecia; Zanabili, Joud; Varela, María Rosario; López-Godino, Oriana; Heras, Inmaculada; Español, Ignacio; Martínez, Carmen; Pérez-Simón, José Antonio; Solano, Carlos; Sureda, Anna; Sierra, Jordi; Sampol, Antonia; Caballero, Dolores
Source
Bone Marrow Transplantation; 20210101, Issue: Preprints p1-10, 10p
Subject
Language
ISSN
02683369; 14765365
Abstract
We performed a retrospective multicenter study including 140 patients with relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL) who underwent allogeneic hematopoietic stem cell transplantation (allo-SCT) from March 1995 to November 2018. Our objective was to analyze long term outcomes. Seventy-four percent had received a previous auto-SCT (ASCT) and the median number of lines pre-allo-SCT was 3 (range 1–9). Three year-event free survival (EFS) and overall survival (OS) were 38% and 44%, respectively. Non-relapse mortality (NRM) at day 100 was 19%. Cumulative incidence of grade III–IV acute graft versus host disease (GVHD) at day 100 was 16% and moderate/severe chronic GVHD at 3 years 34%. Active disease at allo-SCT (HR 1.95, p= 0.039) (HR 2.19, p= 0.019), HCT-CI ≥ 2 (2.45, p= 0.002) (HR 2.33, p= 0.006) and donor age >37 years (HR 2.75, p= 0.014) (HR 1.98, p= 0.043) were the only independent variables both for PFS and OS, respectively. NRM was significantly modified by HCT-CI ≥ 2 (HR 4.8, p= 0.008), previous ASCT (HR 4.4, p= 0.048) and grade III–IV acute GVHD on day 100 (HR 6.13, p= 0.016). Our data confirmed that allo-SCT is a curative option for patients with R/R DLBCL, displaying adequate results for fit patients with chemosensitive disease receiving an allo-SCT from a young donor.